Dr. Dr. Ladan Teimoori-Toolabi
Editorial Board Member
Cancer, Epigenetics, Drug Design, Chemotherapeutic Drug Resistance, Biomarkers
Professor, Pasteur Institute of Iran, Tehran
Editorial board · Peer-reviewed · Open access
Editorial Board
An international board of cancer geneticists, molecular oncologists, and pathologists who steward peer review and scientific quality at JCGB.
20Board members
10Countries
12ORCID iDs available
The board
Members of the JCGB editorial board
The page lists the public board records for JCGB. Affiliations, research-interest terms and ORCID iDs are shown where available in the journal database.
20 members
No matching members
No board members match your search or filter. Try a different term, or clear to see the full board.
Dr. Dr. Shilpi Gupta
Editorial Board Member
HPV, MOLECUALR CANCER BIOLOGY; CANCER STEM CELL RESEARCH
Principal Investigation, Council of Science and Technology, Uttar Pradesh, Uttar Pradesh, Uttar Pradesh
Dr. Dr. Xinyu Chen
Editorial Board Member
Cancer Biology, Cancer Metabolism, Translational Research, Nutrition Study, Biotechnology and Biomedical Science.
Stanford University, Stanford, CA
United States
ORCID profile for Dr. Xinyu ChenORCID
Dr. Dr. Yi Shan
Editorial Board Member
Leukemia, Lymphoma ,MPD, Targeted cancer gene therapy, Cancer biology, Cancer stem cells
University of Massachusetts Medical School
United States
Dr. Dr. Charlie Gourley
Editorial Board Member
Ovarian cancer is the fourth most common cause of female cancer death in the UK. Until recently it has been treated as a single disease entity. There is now considerable evidence to demonstrate that ovarian cancers differ in their tissues of origin, their genetic abnormalities, their responsiveness to chemotherapy and the ultimate outcome for patients. It is our aim to investigate the biology of this disease at the interface between the laboratory and the clinic in order to generate findings that can be directly translated into patient benefit. We do this by characterising the molecular changes that occur in different ovarian cancers and determining how this affects their responsiveness to chemotherapy or novel biological agents. In some instances this has led to the description of novel molecular subtypes.
Chair of Medical Oncology, Honorary Consultant in Medical Oncology, Edinburgh Cancer Research Centre, Western General Hospital.
United Kingdom
ORCID profile for Dr. Charlie GourleyORCID
Dr. Dr. Guru Prasad Maiti
Editorial Board Member
RNA, Cancer Biology, Cell Culture, Gene Expression, DNA, Western Blot Analysis, Immunohistochemistry, Immunofluorescence, Electrophoresis
Assistant Staff Scientist, Oklahoma Medical Research Foundation, Oklahoma City, OK
United States
ORCID profile for Dr. Guru Prasad MaitiORCID
Dr. Dr. Murat Kara
Editorial Board Member
cancer, miRNA, Gene Expression, RNA Isolation, Real-Time PCR.
Department of Medical Genetics School of Medicine, Mugla Sitki Kocman University.
Turkey
Dr. Dr. Yu Cao
Editorial Board Member
PCR Cell Culture Gel Electrophoresis DNA Western Blot Analysis Gene Expression DNA Extraction Cloning SDS-PAGE Cancer Biology Flow Cytometry Immunofluorescence
Moffitt Cancer Center · Department of Immunology.
United States
Dr. Dr. Joshua Curtin
Editorial Board Member
Cancer Biologist and Drug Discovery Expert
Oncology Drug Discovery, Research and Development, Bristol-Myers Squibb.
United States
Dr. Dr. Runjan Chetty
Editorial Board Member
Colorectal cancer, pancreas, molecular pathology, precursor lesions
Deputy Medical Director, Laboratory Medicine Program, University Health Network,Toronto Professor of Pathology, University of Toronto.
Dr. Dr. Anna Brozyna
Editorial Board Member
melanoma, molecular biology, vitamin D, nuclear receptors
Professor and Chair, Nicolaus Copernicus University, Toruń
Dr. Dr. Bijoy Kumar Mohanty
Editorial Board Member
Molecular Biology, Microbiology, Genetics
Dept. of Genetics, Univ. of Georgia.
United States
Dr. Dr. Hou YC
Editorial Board Member
ANXA2 , FAK , tPA , S100A family tumor-related genes and other functions. Tumor Signal Transduction and Regulation. Tumor cells, tissue surface markers and molecular probes screening research. Targeted cancer-targeted nanotherapeutics.
The Lab of Tumor Molecular Cellular Biology Shaanxi Normal University
China
Dr. Dr. Krzysztof Roszkowski
Editorial Board Member
Potential clinical use of biomarkers of oxidative DNA damage and systems of reparation. Optimization of radiotherapy with radiobiology model.
Professor, Nicolaus Copernicus University Collegium Medicum, Bydgoszcz
Dr. Dr. Kumar Pranav Narayan
Editorial Board Member
Cancer Biology, Diagnostics and therapeutics
Professor, Birla Institute of Technology and Science - Hyderabad Campus, Hyderabad, Telangana
Dr. Dr. Maciej Wnuk
Editorial Board Member
Cell stress, Aging, Senescence, DNA methylation, Biology of nucleus, Molecular cytogenetics.
Rzeszów University, Rzeszów
Dr. Dr. Zarmina Ehtesham
Editorial Board Member
Oral Cancer Orofacial Pain Craniomandibular Disorders Oral Medicine Oral, Head and Neck Cancer
Hamdard University
Dr. Dr. Ankita Singh
Editorial Board Member
Cancer Genetics Tumorigenesis Cell Signalling
Post-doctoral student, Harvard Medical School, Boston, MA
United States
ORCID profile for Dr. Ankita SinghORCID
Dr. Dr. Mariantonietta Colozza
Editorial Board Member
Oncology Clinical Oncology Chemotherapy HER2 Malignant Tumors Cancer Therapy
Doctor of Medicine Consultant at Azienda Ospedaliera Santa Maria di Terni
Italy
Dr. Dr. Swapna Apte-Sengupta
Editorial Board Member
Biomarkers, Drug targets, Infectious diseases, cancers, viruses, proteomics, metabolomics
Purdue Univeristy
United States
Some members do not have a public ORCID iD on record; no identifier is inferred when the database field is absent or suppressed. Editors recuse themselves from any manuscript in which they have a conflict of interest.
Governance & accountability
How the board upholds scientific quality
The editorial board is responsible for the scholarly integrity of everything JCGB publishes. Editorial decisions rest on scientific merit and are independent of fees, membership, or any paid service.
What the board does
- Peer-review oversight. Editors assess each submission for fit and rigor and assign qualified reviewers. Review is single-blind (double-blind on request).
- Scope stewardship. The board keeps JCGB focused on cancer genetics, genomics, molecular oncology, and biomarker research.
- Research integrity. Concerns about misconduct, data, or ethics are handled in line with COPE guidance, including corrections and retractions where warranted.
- Confidentiality. Submissions and reviewer identities are treated as confidential throughout the process.
Independence & conflicts of interest
Editors and reviewers declare competing interests and recuse themselves from handling their own submissions or any work where a conflict exists; those manuscripts are managed independently. Payment of an article processing charge, membership, or use of any optional service confers no advantage in review or the likelihood of acceptance.
The board, JCGB & Open Access Pub
The editorial board provides scholarly governance and makes editorial decisions. Open Access Pub, the publisher, provides production, hosting, Crossref DOIs, and preservation infrastructure — it does not make acceptance decisions.
Work with the board
Submit your research — or help review it.
Researchers in cancer genetics and biomarkers who would like to be considered for a reviewer or editorial role are welcome to write to the editorial office with a CV and areas of expertise.